A phase I, open-label, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of weekly intravenous INNO-105 in adult patients with advanced solid malignancies

Trial Profile

A phase I, open-label, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of weekly intravenous INNO-105 in adult patients with advanced solid malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2006

At a glance

  • Drugs Methionine enkephalin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors INNOVIVE Pharmaceuticals
  • Most Recent Events

    • 03 Oct 2006 Status change
    • 28 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top